Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | CA2 | P00918 | 4/20 | 0.48 |
| ▸ | CA7 | P43166 | 4/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411156 | 0.95 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8879116 | 0.93 | ALDH1A1 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2483090 | 0.87 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31024654 | 0.87 | CA12 (0.64) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6640523 | 0.87 | ALDH1A1 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2953498 | 0.86 | ALDH1A1 (0.50) | CA12CA1CA2CA7CA9 | |
| Acetic Acid SCHEMBL27417814 | 0.85 | ALDH1A1 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8156294 | 0.85 | KMT2A (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7833293 | 0.85 | MMP2 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6640962 | 0.85 | TSHR (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113527680-A | Polymer, photosensitive resin composition, pattern forming method, cured film, and electronic component | 信越化学工业株式会社 | 2021-10-22 | — | — | CN | disclosed |
| CN-113527101-A | Novel compound, polymer and method for producing same, photosensitive resin composition, method for forming pattern, cured film, and electronic component | 信越化学工业株式会社 | 2021-10-22 | — | — | CN | disclosed |
| CN-107407878-B | Photosensitive resin composition | 东丽株式会社 | 2020-11-17 | — | — | CN | disclosed |
| CN-111830785-A | Resin composition, method for forming pattern, method for forming cured coating, interlayer insulating film, surface protective film, and electronic component | 信越化学工业株式会社 | 2020-10-27 | — | — | CN | disclosed |
| EP-1951708-B1 | PIPERAZINE DERIVATIVE USEFUL AS A CCR5 ANTAGONIST | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8114879-B2 | 4-piperazine-4-piperidine-1-ketone derivatives; graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis; human immunodeficiency viricides | SCHERING CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| EP-1632479-B1 | Pharmaceutical compositions comprising CCR5 antagonizing piperazine derivatives | SCHERING CORP (US) | 2011-01-12 | — | — | EP | disclosed |
| US-7825121-B2 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION | 2008-08-07 | — | — | US | disclosed |
| EP-1951708-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050375-A2 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| EP-1632479-A2 | Piperazine derivatives useful as ccr5 antagonists | SCHERING CORPORATION (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1175401-B1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2004-04-08 | — | — | US | disclosed |
| US-6689765-B2 | VIRICIDES; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION | 2004-02-10 | — | — | US | disclosed |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-04-10 | — | — | US | disclosed |
| US-6391865-B1 | AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS | SCHERING CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-1175401-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066558-A1 | PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188485-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | CCR5, CXCR3, CCR2 | CA12 4874/4885CA1 4688/4885CA2 4099/4885 |
| US-20030069252-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CA12 4842/4885CA1 4396/4885CA2 3215/4885 |
| US-20040067961-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CA12 4842/4885CA1 4396/4885CA2 3215/4885 |
| US-20060105964-A1 | Piperazine derivatives useful as CCR5 antagonists | CCR5, CCR2, CXCR3 | CA12 4856/4885CA1 4656/4885CA2 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.